COVID-19 Down Under: Australia's Initial Pandemic Experience.

Australia COVID-19 acute respiratory disease case study country economy epidemiology exit strategies mathematical modelling media coverage non pharmaceutical intervention novel coronavirus social political disruption

Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 20 10 2020
revised: 22 11 2020
accepted: 26 11 2020
entrez: 4 12 2020
pubmed: 5 12 2020
medline: 15 12 2020
Statut: epublish

Résumé

The following case study aims to provide a broad overview of the initial Australian epidemiological situation of the novel coronavirus disease (COVID-19) pandemic. We provide a case presentation of Australia's current demographic characteristics and an overview of their health care system. The data we present on Australia's COVID-19 situation pertain to the initial wave of the pandemic from January through to 20 April 2020. The results of our study indicate the number of reported COVID-19 cases in Australia reduced, and Australia initially managed to successfully flatten the curve-from an initial doubling time of 3.4 days at the end of March 2020 to a doubling time of 112 days as of 20 April 2020. Using SEIR mathematical modelling, we investigate a scenario assuming infections increase once mitigation measures are lifted. In this case, Australia could experience over 15,000 confirmed cases by the end of April 2020. How Australia's government, health authorities and citizens adjust to preventative measures to reduce the risk of transmission as well as the risk of overburdening Australia's health care system is crucial. Our study presents the initial non-pharmaceutical intervention measures undertaken by the Australian health authorities in efforts to mitigate the rate of infection, and their observed and predicted outcomes. Finally, we conclude our study by presenting the observed and expected economic, social, and political disruptions Australians may endure as a result of the initial phase of the pandemic.

Identifiants

pubmed: 33271867
pii: ijerph17238939
doi: 10.3390/ijerph17238939
pmc: PMC7730791
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Swiss Med Wkly. 2020 Mar 16;150:w20224
pubmed: 32176808
Emerg Infect Dis. 2020 Dec;26(12):2844-2853
pubmed: 32985971
Lancet. 2020 Feb 29;395(10225):689-697
pubmed: 32014114
Med J Aust. 2020 Jun;212(10):463-467
pubmed: 32306408
Lancet. 2020 Feb 29;395(10225):664-666
pubmed: 32061311
N Z Med J. 2020 Apr 3;133(1512):10-14
pubmed: 32242173
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Nature. 2017 Jul 19;547(7663):306-310
pubmed: 28726833
Lancet Glob Health. 2015 Apr 27;3 Suppl 2:S13-20
pubmed: 25926315
Med J Aust. 2020 May;212(9):393-394.e1
pubmed: 32146721
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
BMJ. 2020 Mar 17;368:m1066
pubmed: 32184233
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
Lancet. 2018 Jun 2;391(10136):2236-2271
pubmed: 29893224
Nat Commun. 2020 Nov 11;11(1):5710
pubmed: 33177507

Auteurs

Matthew James Cook (MJ)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.
Melbourne School of Population and Global Health, University of Melbourne, Bouverie Street, Carlton, VIC 3053, Australia.

Gabriela Guizzo Dri (GG)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Prishanee Logan (P)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Jia Bin Tan (JB)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Antoine Flahault (A)

Institute of Global Health, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH